Your thesis of my being a "pump and dumper" might make sense if I wasn't exclusively accumulating with every price attack you and your other gangsters have thrown at Affymax...But if there's any dumping it certainly isn't coming from me. My stake just continues to grow and I have NEVER sold a single share!!! The BASH TRASH you work for or with has been the agent of any "DUMP" !!!
The agency focused in on the plant's quality control unit, saying it was relying on customers to identify proble in an effort to hit specifications. It documented employees confessing to manipulating data to hide problems from the agency. They told inspectors that when it was known there was going to be an inspection, high-pressure liquid chromatography equipment and personnel computers were removed from the plant to "conceal data manipulations."
And there were so many bash trash saying "COULDN'T POSSIBLY FRESENIUS' PROBLEM"...RIGHT!!!
German drugmaker Fresenius received a scathing warning letter in July for a drug plant in India. Now, a blood-products plant in Puerto Rico has been sent a warning for a labeling issue which the agency said should have been resolved months, even years ago.
The FDA Tuesday posted the letter that the drugmaker's Fenwal operation received for an inspection in April, a follow-up to a 2012 visit. Primarily, the agency was concerned about the company's failure to document and investigate customer complaints about mislabeled bags even although the products had already been shipped. "Our inspection in 2012, and the current inspection, found that you have received multiple consumer complaints related to mislabeled bags, inadequate bag size, defective product components, and product mix-ups" that were left unresolved.
Further, in a repeat violation, the plant was criticized for not writing a procedure to make sure that products get the right labels and procedures to "prevent mix-ups and cross-contamination" by keeping different products separated from each other, even though the facility has been getting complaints since 2010 about the problem. The agency was also upset that the plant still wasn't submitting field alert reports, or FARs, even though it was told in 2012 that it needed to. As a result, the company now is having to recall its Adsol blood preservative as well as an anticoagulant solution, the FDA pointed out.
The agency focused in on the plant's quality control unit, saying it was relying on customers to identify problems that should have been corrected at the plant. The complaints show that the unit is not "fulfilling its responsibility to assure the identity, strength, quality, and purity of your licensed biological drug product(s)," the letter says.
In July, the company's oncolytic API plant in Kalyani, India, was savaged in a warning letter that said employees lied about having blended APIs that failed quality tests into batches that passed in an effort
The GREAT IRONY of your personal attacks on me is that it is your BASH TRASH WHACK PACK that has done 100% of the "shearing" !!! I'm still as convinced as one can be that Omontys is coming back and that Affymax will be acquired by Takeda and YOU WILL GET DESTROYED if you remain short...but what the hell do I know, I only worked on such things as a Pharma Industry Merger and Acquisition Investment banker for over 30 years versus your decades of ambulance chasing legal practice.
The exact same way we'll get back to the mid $74's, $80's, $90's and over $100's THIS YEAR (2013)...Shorts in denial of spectacular results and and a truly inspiring strategic action plan...BTW, fwiw there is a fairly credible rumor that another strategic acquisition is in the works (shhhh...let's keep this our secret)...
GWP...I completely agree on your FUNDAMENTALS POINT...Fundamentals (HISTORY) says that there are NO DRUGS with the mortality profile of Omontys that have been permanently pulled. Out of the 53 that have been pulled since 1960 ONLY ONE even came close to O's mortality and AE profile and it had a half dozen almost identical antibiotics with great safety profile. CONVERSELY THERE ARE HUNDREDS OF DRUGS WITH FAR WORSE MORTALITY PROFILE ON THE MARKET TODAY!!! Just being with Tylenol...which CNN had a feature story just a couple of days ago that there have been an average of 150 FATALITIES PER YEAR FROM TYLENOL OVER THE PAST 10 YEARS!!! Using your contorted logic Tylenol should have been pulled a long time ago.
The one thing you have been working like crazy is the fact that the investigation isn't over and Omontys hasn't (YET-YET-YET) been restored to the market...and as long as such uncertainty exists the BASH TRASH WHACK PACK can and will say just about anything to spread fear...That "advantage" will soon be ending and I hope like hell that you've held every one of your short shares when that happens!!! You won't be able to offer up your twisted stories once the truth has been revealed and Omontys returned to market!!! You'll just disappear, broke and broken after almost a year of spewing forth your perverse garbage hurting g-d knows how many people in the process...YOU MY FRIEND ARE THE JUDAS GOAT!!!
They're about to get a super-soaking when the TSUNAMI BLINDSIDES THEM !!! I think starting tomorrow (unless you include TODAY'S TSUNAMI WARNING)...Seek shelter on higher ground IMMEDIATELY !!!
Welcome home Johnny...wasn't there a Civil War song something like that:-) Where you been brother, we've missed you!!!
Pharmaman, don't know why they just don't use my numbers since they've proven far more accurate than any of my Wall Street Brethren :-) So as a reprise...The following are ALL Non-GaaP:
Q3 EPS= $1.65
Q4 EPS= $1.95
2013 TOTAL EPS $5.73
PHARMA INDUSTRY AVERAGE P/E (depending on source) = 20 to 24X so let's just use midpoint of 22 X $5.73=$126.06
and just for a few giggles, let's use a Neutral PEG of 1.0 (30X P/E)=$171.90
And it's selling for $57.87 at the close today...GIMME A BREAK !!! Still the BEST VALUE OPPORTUNITY at least in the biotech/pharma domain...
HERE'S THE CURRENT CONSENSUS:
Analyst Opinion Get Analyst Opinion for:
Mean Recommendation (this week): 1.5
Mean Recommendation (last week): 1.3
* (Strong Buy) 1.0 - 5.0 (Sell)
Price Target Summary
Mean Target: 76.70
Median Target: 76.50
High Target: 90.00
Low Target: 65.00
No. of Brokers: 10
Data provided by Thomson/First Call
And they will be giving you the same responses when it goes back to $60, $70's (before earnings), $80's (after Q3 earnings) heading toward $100 by end of this year as I have been saying now for nine months and minus this little stutter step been 100% on trajectory!!! The difference between idiots like you and pros like me is that I actually really do some heavy lifting when I perform analysis versus you just flapping your keyboard with totally unsubstantiated nonsense. But the good news for you is that there seems to be a place for bash trash like you on virtually every one of these boards, so when this fails you you'll have any number of places to go do your dirty little job.
Feces, it always amazes me how people like you get so bold when the wind has been to your back for a few days. The "bonus" payouts to Novartis and Biovectra are RESULTS dependent (how convenient for you to ignore that) though I have NO DOUBT that they'll get paid based on Q's continued performance and those performance commitments to both Biovectra and Novartis.
BTW, have you ever thought that your screen name alone REMOVES EVERY SHRED OF CREDIBILITY YOU MIGHT HAVE HAD???
Your few days with Q in your favor have come and are about to be long since gone as they head toward $1.65 non-gaap earnings in Q3 and $1.95 in Q4...but just check my accuracy record on EPS estimates if you have any doubts...Been beating the crappola out of every analyst on the street!!! And will most assuredly put jerks like you in their ultimate place even if you happened to have a few (short) days that made you so bold!!!
Yes, I saw...but that's how cookies crumble and WHY I am NOT a trader (at least as a rule). But I made some money on UNXL, really don't understand their business nor what was going on and I decided the money was much better placed on Questcor which I KNEW had been kicked back down to ridiculous levels!!! A few weeks from now we can re-examine the wisdom of this move :-)
Every Quarter I've been told my EPS estimates have been overly aggressive, but they're built from the bottom up using a model which is an exact duplicate of Q's financial reporting. Other than Q1 where there were totally unexpected one time events that caught everyone flat footed, my model's estimates have been on or within a few cents (always a few cents too low) of actuals. So what will be said when it hits the target again...Still got LUCKY? This is what HARD ANALYSIS is all about and I can guarantee you that I spend far more time on this than any analyst on the street has the time to do (one of the benefits of retirement :-)
I'll go one step further than P-Man...I believe that if it was not for the concessionary final DNA test to appease Fresenius that the investigation WOULD ALREADY BE OVER (after all they only had to investigate JUST 3 fatalities, though I am not in any way diminishing the impact to those families). In the meanwhile Affymax has enough cash and such a low burn rate that they could withstand years of this even if many of the shareholders don't have such patience...I DO !!!
The bet is for a 25 year old McCallan...it doesn't get much better than that and I plan on enjoying the bottle P-Man will send me over the holidays!!!
I've been IN Q with an average price of under $20 on my core holdings and about $60 on my trading shares that Pharmaman got me into :-) So I don't anticipate any embarrassment :-)
I'm not a trader but I have NO DOUBT even those shares will be highly profitable and propel me to win that bottle of McCallan from P-Man!!! Q just has to get across the $90 mark by the EOY to win the bet.